hydrochlorothiazide has been researched along with Apparent Mineralocorticoid Excess Syndrome in 1 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amiloride is a drug that selectively reduces the aldosterone-sensitive Na+/K+ exchange and could be effective in the management of mineralocorticoid excess syndrome (MCES)." | 1.46 | Amiloride Is Effective in the Management of Abiraterone-Induced Mineralocorticoid Excess Syndrome without Interfering with Its Antineoplastic Activity. ( Bedussi, F; Berruti, A; Dalla Volta, A; Ferrari, V; Fragni, M; Galli, D; Lazzari, B; Memo, M; Roca, E; Rossini, E; Sigala, S; Valcamonico, F; Vezzoli, S, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bedussi, F | 1 |
| Galli, D | 1 |
| Fragni, M | 1 |
| Valcamonico, F | 1 |
| Rossini, E | 1 |
| Dalla Volta, A | 1 |
| Vezzoli, S | 1 |
| Roca, E | 1 |
| Ferrari, V | 1 |
| Lazzari, B | 1 |
| Memo, M | 1 |
| Sigala, S | 1 |
| Berruti, A | 1 |
1 other study available for hydrochlorothiazide and Apparent Mineralocorticoid Excess Syndrome
| Article | Year |
|---|---|
Amiloride Is Effective in the Management of Abiraterone-Induced Mineralocorticoid Excess Syndrome without Interfering with Its Antineoplastic Activity.
Topics: Amiloride; Androgens; Androstenes; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Comb | 2017 |